Modulation of behavioral sensitization to cocaine by NAALADase inhibition.
Sensitization to cocaine has been attributed to alterations in excitatory amino acid and dopamine neurotransmission in the mesolimbic system. The present study sought to determine whether inhibition of NAALADase, an enzyme that cleaves glutamate from the endogenous neuropeptide, N-acetyl-aspartyl-glutamate (NAAG), attenuates sensitization to the psychomotor stimulant effects of cocaine. Rats received daily injections of cocaine (20.0 mg/kg/day; i.p.) or saline for 5 days. Fifteen minutes prior to these injections they received an i.p. injection of the NAALADase inhibitor, 2-PMPA (50.0-100 mg/kg), or vehicle. Locomotor activity and stereotypy produced by a challenge dose of cocaine (15.0 mg/kg) were assessed 3 days later. Acute cocaine administration increased locomotor activity in control animals. In animals with a prior history of cocaine administration, the behavioral response to cocaine was significantly enhanced. In animals that had received 2-PMPA in combination with cocaine, the enhancement of cocaine-induced locomotor activity was attenuated. No alteration in cocaine-evoked activity was observed in animals that had received once daily injections of 2-PMPA, alone. Acute administration of 2-PMPA also did not modify saline-induced locomotor activity or activity produced by an acute cocaine challenge. These data demonstrate that NAALADase inhibition attenuates the development of sensitization to the locomotor-activating effects of cocaine. Furthermore, this action cannot be attributed to an antagonism of the acute effects of cocaine.
Shippenberg
T S
TS
Integrative Neuroscience Unit, Behavioral Neuroscience Laboratory, NIH/NIDA Intramural Research Program, Baltimore, Maryland 21224, USA. tshippen@intra.nida.nih.gov
Rea
W
W
Slusher
B S
BS
D000818:Animals; D002268:Carboxypeptidases / Q000037:antagonists & inhibitors*; D003042:Cocaine / Q000494:pharmacology*; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology*; D043425:Glutamate Carboxypeptidase II; D008297:Male; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D009943:Organophosphorus Compounds / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley
C402107:2-(phosphonomethyl)pentanedioic acid; D018765:Dopamine Uptake Inhibitors; D009943:Organophosphorus Compounds; D002268:Carboxypeptidases; D043425:Glutamate Carboxypeptidase II; D003042:Cocaine